We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





World's First 5-Minute Real-Time PCR Instrument Debuts at ADLM 2024

By LabMedica International staff writers
Posted on 30 Jul 2024

OnsiteGene Inc. More...

(San Diego, CA, USA) is introducing the new XDive, the world's first 5-minute real-time PCR instrument, at the Association for Diagnostics & Laboratory Medicine (ADLM) 2024 conference. This groundbreaking innovation completes 40 thermal cycles and real-time fluorescent imaging in just five minutes while maintaining sensitivity comparable to leading brands on the market.

OnsiteGene's XDive 5-minute PCR is an ultra-fast real-time PCR analysis platform that integrates high-speed thermal cycling, ultra-fast PCR reaction reagents, and real-time fluorescence data acquisition workflows. XDive can perform up to 16 ultra-fast reactions per experiment, providing moderate sample throughput and maximum working flexibility. It uses proprietary heating blocks, sensors, and algorithms to achieve ultra-fast ramp rates and superior temperature control accuracy. Its optical system consists of four fluorescence channels, which can be detected by multiplex real-time PCR analysis in minutes. XDive's unique TaqMan chemistry has been optimized for ultra-fast operating conditions. XDive reaction tubes accommodate reaction volumes on conventional PCR instruments, resulting in highly accurate and reproducible results for very ultra-fast fluorescence PCR analysis. The software structure of the system is simple and reasonable, and it is easy to operate.

OnsiteGene's original XDive 5-minute ultra-fast real-time PCR instrument can be easily integrated into new systems as an OEM module, significantly increasing productivity and flexibility, as well as reducing application costs. With OnsiteGene’s 5 minutes superfast magnetic bead nucleic acid extraction instrument (Xtractor) and reagent, users can also develop new ultra-fast real-time PCR applications on the XDive system with 16 sample throughput in as fast as 10 minutes from sample to answer for point-of-care molecular testing and other applications. The instrument has received FDA Emergency Use Authorization (EUA) for COVID-19 and Monkeypox testing using swab or saliva samples.

XDive's editable panel technology simplifies the regulatory process for developing test kits and syndromic panels, significantly reducing time, cost, and risk. The superfast master mix used in the XDive instrument is in a dried form, allowing for easy shipping and storage at room temperature with a shelf life of 6 months. OnsiteGene has also developed the XPrep module, designed to extract RNA/DNA and seamlessly load XDive cartridges. With the XPrep module, XDive instruments provide a comprehensive and flexible sample-to-answer platform with up to 96-sample throughput, up to 256 multiplexing targets, and a 30-minute turnaround time.

Related Links:
OnsiteGene Inc.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
HPV Test
Allplex HPV28 Detection
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.